123 results
8-K
EX-99.1
DMAC
DiaMedica Therapeutics Inc.
7 Aug 24
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
4:32pm
Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management’s current
424B3
DMAC
DiaMedica Therapeutics Inc.
18 Jul 24
Prospectus supplement
5:28pm
could cause the market price of our common shares or trading volume to decline.
We could be subject to securities class action litigation, which … is expensive and could divert management attention.
In the past, securities class action litigation has often been brought against a company following
8-K
EX-10.1
DMAC
DiaMedica Therapeutics Inc.
26 Jun 24
DiaMedica Therapeutics Announces $11.8 Million
8:16am
that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.
(j) Litigation. Except as set forth … any such claim, litigation, arbitration, action, suit, investigation or proceeding; (D) has not received written notice that any governmental
8-K
EX-99.1
vs4oxm pgms5
26 Jun 24
DiaMedica Therapeutics Announces $11.8 Million
8:16am
8-K
EX-99.2
921 65xng49h9ecm
26 Jun 24
Regulation FD Disclosure
8:01am
8-K
czvdowwa1l9b0dl
26 Jun 24
Regulation FD Disclosure
8:01am
8-K
EX-10.1
4qltd
23 May 24
Departure of Directors or Certain Officers
4:00pm
8-K
EX-99.1
8lonrfn66ih hkpx
8 May 24
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
4:30pm
8-K
EX-99.1
4uj7kj fqjk
19 Mar 24
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
4:16pm
8-K
EX-99.1
7e7alt ad8
13 Nov 23
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
4:52pm
8-K
EX-99.1
i5xec2gr2v7sev 19fe
14 Aug 23
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
4:25pm
424B3
w1kjvtxa7u b9
10 Jul 23
Prospectus supplement
4:16pm